Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tecentriq plus chemotherapy and Avastin delays disease progression and death.
Cancer today feels like AIDS in the mid-1990s.
In non-small cell lung cancer, new drugs like brigatinib and crizotinib can dramatically shrink tumors with an ALK alteration.
Lorlatinib shrinks tumors in half of patients previously treated with older ALK inhibitors.
Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.
Median overall survival was 15.9 for the combination versus 11.3 months for chemotherapy alone.
Treatment with Opdivo appears to work well for HIV-positive people in small study.
Immunotherapy led to better outcomes for patients with inoperable non-small-cell lung cancer.
Targeted therapy approved first-line treatment of cancer with specific genetic mutations.
Targeted therapy reduced risk of disease progression or death by about 50 percent.
Communities focused on specific lung cancer genetic mutations offer patient support and accelerate research.
Immunotherapy combo reduced the risk of disease progression or death in a Phase III study.
Novel technique lets researchers control common cancer pathway in the lab with pulses of light.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.